WuXi AppTec Content Team Editor
A few days ago, SCYNEXIS announced that its innovative oral antifungal investigational therapy ibrexafungerp has received positive interim results in two Phase 3 clinical trials, continuing to show that ibrexafungerp has the ability to treat difficult-to-treat hospital settings. Potential for the treatment of fungal infections.
Ibrexafungerp is a glucan synthase inhibitor with a unique structure that combines the good activity of glucan synthase inhibitors with the potential of oral and intravenous administration Combined, the flexibility promises widespread use in both inpatient and outpatient settings. The drug is currently being developed to treat fungal infections mainly caused by Candida and Aspergillus. It exhibits broad-spectrum antifungal activity in in vitro and in vivo studies. Previously, the US FDA has granted ibrexafungerp Qualified Infectious Disease Product Designation (QIDP), Fast Track Designation, and Orphan Drug Designation.
In the open-label, single-arm FURI study, oral ibrexafungerp was used to treat patients with severe fungal infections who were intolerant of standard antifungal therapy or who had resistant fungal infections. In another open-label, single-arm CARES study, oral ibrexafungerp was used to treat infections caused by Candida auris, a fungus that is often multidrug-resistant and associated with high mortality.
Trial results showed that of 131 patients included in both studies, 61.1% achieved complete remission, partial remission or clinical improvement, and 22.1% had stable disease (for This is a good result for patients with severe progressive fungal infection), 11.5% of patients did not respond. Please see the table below for specific data.
Image source: Reference [1]
“We are very pleased to share these positive interim data that continue to validate ibrexafungerp’s ability to combat a wide range of serious and potentially deadly infectious diseases,” said Dr. Marco Taglietti, President and CEO of SCYNEXIS. ” These studies are key to building our broad pipeline of antifungal drugs to help millions of patients with severe fungal infections around the world.”
References:
[1] SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp’s Potency Against Severe Fungal Infections. Retrieved April 23, 2022, from https:https://www.globenewswire .com/news-release/2022/04/22/2427322/0/en/SCYNEXIS-Announces-Positive-Interim-Data-from-Phase-3-FURI-and-CARES-Studies-Highlighting-Oral-Ibrexafungerp-s -Potency-Against-Severe-Fungal-Infections.html
Disclaimer: The WuXi AppTec content team focuses on global biomedical health research progress. This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec’s position, nor do they represent WuXi AppTec’s support or opposition to the views expressed in this article. This article is also not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Copyright note: This article is from WuXi AppTec’s content team. Individuals are welcome to forward it to the circle of friends, and media or institutions are not allowed to reprint it to other platforms in any form without authorization. For reprint authorization, please reply to “Reprint” on the WeChat public account of “WuXi AppTec” for instructions on reprinting.
Share, LikeLike, Watching, focus on global biomedicine Health innovation